- $59.31m
- $52.81m
- $2.03m
Durect Corp Expected To Post A Loss Of 1 Cent A Share: Earnings Preview
Durect Corp Expected To Post A Loss Of 1 Cent A Share: Earnings Preview
Brief: DURECT Reaches Enrollment Milestone In Phase 2B Ahfirm Trial
Brief: DURECT Corp And Innocoll Announce U.S. Launch Of Posimir
Brief: Durect Corp - QTRLY Loss Per Share $0.05
Durect Corp Expected To Post A Loss Of 5 Cents A Share: Earnings Preview
Brief: DURECT Corporation Appoints Timothy M. Papp As Chief Financial Officer
Durect Corp Reports Results For The Quarter Ended In March: Earnings Summary
Brief: Durect Corporation Reports First Quarter 2022 Financial Results And Update Of Programs
Durect Corp Expected To Post A Loss Of 5 Cents A Share: Earnings Preview
Durect Corp Expected To Post A Loss Of 5 Cents A Share: Earnings Preview
Durect Corp Reports Results For The Quarter Ended In December: Earnings Summary
Brief: Durect Corporation Qtrly Net Loss Per Common Share, Basic And Diluted $0.03
Durect Corp Expected To Post A Loss Of 5 Cents A Share: Earnings Preview
Brief: Durect Says CFO Michael Arenberg Resigned
Brief: Durect Corporation Doses First European Patient In Phase 2B Study Of Larsucosterol In Severe Alcohol-Associated Hepatitis
Durect Corp Expected To Post A Loss Of 5 Cents A Share: Earnings Preview
Brief: Durect And Innocoll Announce A $136 Million U.S. Licensing Agreement For Posimir® (Bupivacaine Solution)
Brief: Durect Corporation Expands Board Of Directors With Appointment Of Biopharmaceutical Industry Finance Veteran Peter Garcia